CNS Pharmaceuticals Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, has completed shipping its Active Pharma Ingredient (API) to both Maryland-based Pharmaceutics International Inc., (Pii) and Italian BSP Pharmaceuticals S.p.A., (BSP), respectively, for the production of Berubicin.
 
"As we continue to prepare for our upcoming Berubicin Phase 2 trial, ensuring proper manufacturing and delivery of drug product is a key priority," stated John Climaco, CEO of CNS Pharmaceuticals. "We are excited to execute on yet another key milestone, and deliver Berubicin's API to our trusted partners PII and BSP. We will continue our focus on executing upon all of the necessary steps as we look to pave the way for our upcoming U.S. Phase 2 trial, expected to initiate during the fourth quarter of this year."
 
CNS previously entered into manufacturing contracts with Pii and BSP for the production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors. The decision to implement a binary manufacturing strategy mitigates COVID-19 related manufacturing risks for the upcoming Phase I study in Poland and the upcoming U.S. Phase 2 trial. The first API shipments to PII and BSP commenced in June.